Review Registration - Organization

This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.

Registration ID: 422131
Submitted by lobbyist on: August 7, 2014 01:04:38 PM
Accepted by Registrar on: August 12, 2014 08:54:25 AM

Designated Filer Information

Keon, James J  
4120 Yonge Street Suite 409  
Toronto, ON, M2P 2B8
416-223-2333
Canada  

Organization Information

Canadian Generic Pharmaceutical Association (CGPA)  
The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers.
4120 Yonge Street Suite 409  
Toronto, ON, M2P 2B8
416-223-2333
Canada  

Relevant Affiliates

The client has no relevant affiliates.

Government or Government Agency Funding


The organization does not receive any funding from a government or government agency.

Other Controlling or Directing Interests

The organization has no other controlling or directing interests.

Active Registration Period

August 7, 2014  
February 3, 2015  

Organization's In-House Lobbyists

 



Name: Connell, Jeff
 
August 7, 2014  
Inactivation Date: February 27, 2015

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Introduction, modification or repeal of legislation, a bill or regulation

Development of a policy framework for addressing and reimbursing subsequent entry biologics. Discussion of potential expansion of Reference Drug Program. Development of policy concerning use of brand drug coupon cards. Implementation of the pan-Canadian pricing agreement for generic drugs. Addressing delays in listing certain generic drugs due to requirement of a Ministerial Order and discussion of alternatives. Development of a policy to address companies that cannot meet supply commitments for generic drugs. Discussion of listing process for generic drugs.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health August 7, 2014

Name: Keon, James
 
August 7, 2014  
Inactivation Date: February 27, 2015

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Introduction, modification or repeal of legislation, a bill or regulation

Development of a policy framework for addressing and reimbursing subsequent entry biologics. Discussion of potential expansion of Reference Drug Program. Development of policy concerning use of brand drug coupon cards. Implementation of the pan-Canadian pricing agreement for generic drugs. Addressing delays in listing certain generic drugs due to requirement of a Ministerial Order and discussion of alternatives. Development of a policy to address companies that cannot meet supply commitments for generic drugs. Discussion of listing process for generic drugs.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health August 7, 2014

Name: Tam, Julie
 
February 17, 2015  
Inactivation Date: February 27, 2015

BC Public Office Background

This individual has not held any public office positions in BC.

Lobbying Activities

Health

Awarding, amendment or termination of a contract, grant or financial benefit

Development, establishment, amendment or termination of any program, policy or decision

Introduction, modification or repeal of legislation, a bill or regulation

Development of a policy framework for addressing and reimbursing subsequent entry biologics. Discussion of potential expansion of Reference Drug Program. Development of policy concerning use of brand drug coupon cards. Implementation of the pan-Canadian pricing agreement for generic drugs. Addressing delays in listing certain generic drugs due to requirement of a Ministerial Order and discussion of alternatives. Development of a policy to address companies that cannot meet supply commitments for generic drugs. Discussion of listing process for generic drugs.

Target Contacts

Target Type Name Title or Constituency Date Added
Public Agency Health February 17, 2015